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A bs tr ac t
Background
Dupuytren’s disease is a benign fibromatosis of the hands and fingers that leads to 
flexion contractures. We hypothesized that multiple genetic and environmental factors 
influence susceptibility to this disease and sought to identify susceptibility genes to 
better understand its pathogenesis.
Methods
We conducted a genomewide association study of 960 Dutch persons with Dupuy-
tren’s disease and 3117 controls (the discovery set) to test for association between 
the disease and genetic markers. We tested the 35 single-nucleotide polymorphisms 
(SNPs) most strongly associated with Dupuytren’s disease (P<1×10−4) in the discovery 
set in three additional, independent case series comprising a total of 1365 affected 
persons and 8445 controls from Germany, the United Kingdom, and the Netherlands.
Results
Initially, we observed a significant genomewide association between Dupuytren’s 
disease and 8 SNPs at three loci. Tests of replication and joint analysis of all data 
from 2325 patients with Dupuytren’s disease and 11,562 controls yielded an asso-
ciation with 11 SNPs from nine different loci (P<5.0×10−8). Six of these loci con-
tain genes known to be involved in the Wnt-signaling pathway: WNT4 (rs7524102) 
(P = 2.8×10−9; odds ratio, 1.28), SFRP4 (rs16879765) (P = 5.6×10−39; odds ratio, 1.98), 
WNT2 (rs4730775) (P = 3.0×10−8; odds ratio, 0.83), RSPO2 (rs611744) (P = 7.9×10−15; 
odds ratio, 0.75), SULF1 (rs2912522) (P = 2.0×10−13; odds ratio, 0.72), and WNT7B 
(rs6519955) (P = 3.2×10−33; odds ratio, 1.54).
Conclusions
This study implicates nine different loci involved in genetic susceptibility to Dupuy-
tren’s disease. The fact that six of these nine loci harbor genes encoding proteins in 
the Wnt-signaling pathway suggests that aberrations in this pathway are key to the 
process of fibromatosis in Dupuytren’s disease.
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Dupuytren’s disease is a benign fibro­matosis of the hands and fingers, giving rise to the formation of nodules and cords 
and often leading to flexion contractures (Fig. 1 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). The prev alence 
of Dupuytren’s disease is reported to be between 
0.2% and 56.0%.1 Men are more often affected 
than women, but by the ninth decade of life, the 
incidence in women is the same as that in men.2,3 
Standard treatment consists of surgical excision or 
transection of pathologic nodules and cords, but 
other methods of treatment are emerging.4,5 There 
is no cure for the disease, however, and reported 
recurrence rates range from 8% to 66%, depend-
ing on the treatment.6,7 The pathogenesis of Du-
puytren’s disease is not fully understood.
The clustering of cases of Dupuytren’s disease 
in families suggests a genetic influence on the 
onset of disease; however, it is probably a complex 
condition in which several genetic and environ-
mental risk factors are involved, each contributing 
in small part to susceptibility to the disease. To 
date, a limited number of small candidate-gene 
association studies have been performed,8,9 but no 
causal genes have been identified. To identify com-
mon genetic variants associated with this disease, 
we carried out a genomewide association study 
involving 960 persons with Dupuytren’s disease 




Participants provided written informed consent, 
and we obtained approval from an institutional re-
view board to carry out the study. Between 2007 
and 2010, we recruited 960 patients with Dupuy-
tren’s disease through the outpatient clinics of the 
plastic surgery departments of six hospitals in the 
Netherlands. All 3117 controls for the discovery set 
were drawn from LifeLines, a large, population-
based cohort study being conducted in the north-
ern Netherlands.10 We obtained blood samples for 
replication studies from 189 Dutch patients with 
Dupuytren’s disease, as well as from 561 Dutch 
controls who were newly enrolled in LifeLines and 
for whom genotyping data were already available; 
from 711 British patients with Dupuytren’s dis-
ease, as well as from 5984 controls from the Well-
come Trust Case Control Consortium 2 (WTCCC, 
1958 British Birth Cohort, and U.K. National Blood 
Service) for whom genotyping data were already 
available11; and from 465 German patients with 
Dupuytren’s disease, as well as from 1900 con-
trols, for 1618 of whom genotyping data were al-
ready available (1164 from the PopGen study at the 
University of Kiel and 454 from KORA [Coopera-
tive Health Research in the Region of Augsburg] 
at the Helmholtz Center Munich in Neuherberg) 
(Table 1). (A detailed description of case patients 
and controls is provided in the Supplementary 
Appendix.) Participants reported ancestry by means 
of a multiple-choice questionnaire, the choices be-
ing Dutch, European (specifying country), and 
other (specifying country). DNA samples were ob-
tained from either blood samples (in the Dutch 
and German case series) or saliva (in the U.K. 
case series).
Tests for Association
We genotyped the Dutch samples (discovery set) 
and control samples (LifeLines) with Illumina 
HumanCytoSNP-12 arrays, comprising 301,232 
SNPs, and called SNPs with the use of the Illu-
mina algorithm (Genome Studio, version 2.10.1). To 
test for replication of association, we selected SNPs 
that showed an association in the discovery set 
with a P value of less than 10−4. We confirmed the 
integrity of these associations by manually in-
specting genotype clusters and selected two SNPs 
to represent each independent locus (see the Sup-
plementary Appendix). We genotyped the SNPs 
selected for tests of replication in the Dutch and 
British persons by means of KASP by Design as-
says (KBioscience). We used Human SNP Array 6.0 
(Affymetrix) to genotype these SNPs in the German 
persons. To test for replication of SNPs for which no 
direct or tag SNPs were present on the Affy metrix 
6.0 platform, we genotyped the selected SNPs in 
both the German persons affected with Dupuy-
tren’s disease and a separate control series, using 
GenomeLab SNPstream (Beckman Coulter).
Statistical Analysis
We excluded from the analysis specific SNPs and 
data from specific samples, as described previ-
ously.12,13 SNPs with call rates of less than 95%, 
a minor-allele frequency of less than 0.01, or devia-
tion from Hardy–Weinberg equilibrium (P<0.0001) 
were excluded, as were samples with call rates be-
low 99% or with a discrepancy between recorded 
sex and genotype-inferred sex. We also excluded 
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relatives and ethnic outliers (see the Supplemen-
tary Appendix). Because genomewide association 
studies are performed in patients and controls in 
the same ethnic group, we used multidimensional 
scaling in the study participants and persons in 
HapMap to identify nonwhites in our study pop-
ulation (i.e., ethnic outliers). We compared geno-
type prevalence in cases and controls with the 
use of a basic chi-square allelic test with 1 degree 
of freedom and calculated the overdispersion fac-
tor of association test statistics (genomic control 
inflation factor, λgc) with the use of observed ver-
sus expected values for all SNPs by means of the 
PLINK software package (version 1.07). Principal-
component analysis was performed with the use 
of EIGENSTRAT software to control for population 
stratification. We conducted conditional analysis 
with the use of SNPTEST, version 2, when more 
than one SNP with a significant genomewide as-
sociation clustered at a certain region.
We excluded SNPs from tests of replication 
if they had a call rate below 98% or deviated 
from Hardy–Weinberg equilibrium (P<0.0001), and 
we excluded samples with call rates below 95%. 
We carried out a joint analysis of the discovery 
and replication phases with the use of Cochran– 
Mantel–Haenszel stratification. In the U.K. control 
series, not all SNPs selected for replication were 
available on the Illumina 1.2M and Affymetrix 
6.0 genotyping platforms, which were used by 
WTCCC; in some cases, we used tag SNPs, and for 
four replication SNPs, we used imputed WTCCC 
control data (Table 1 in the Supplementary Ap-
pendix) generated with BEAGLE Genetic Analysis 
Software Package 3.2 and based on the HapMap 
phase 2 reference of Centre d’Etude du Polymor-
phisme Humain (CEPH) persons of European an-
cestry (CEU). In the German series, several SNPs 
selected for replication were not available on the 
Affymetrix 6.0 platform; in these cases, tag SNPs 
were used as well (Table 1 in the Supplementary 
Appendix). We used multiple genotyping platforms 
for the control cohorts in the replication phase. 
Since the replication signals were in the same di-
rection and of the same magnitude as the discovery 
results, it is unlikely that the confirmatory results 
were due to biased genotyping. We checked for 
interplatform reproducibility by comparing geno-
types of the same samples between different plat-
forms and found concordance rates of more than 
99.99% (see the Supplementary Appendix).
We were not able to correct for population 
stratification in the samples used to test for rep-
lication because we genotyped only a limited num-
ber of SNPs in this phase. Meta-analysis of the 
discovery and replication data was also performed 
with PLINK software. We performed an analysis 
with the use of the Gene Relationships across 
Implicated Loci (GRAIL) statistical strategy involv-
ing hg18 and PubMed data sets (December 2006), 
with the 11 SNPs that had a significant genome-
wide association as query regions.14
R esult s
Genomewide Associations
Data obtained through genomewide genotyping 
of affected persons and controls are stored at 
the European Genome–Phenome Archive (acces-
sion number, EGAS00000000043). We excluded 
66,293 SNP genotypes because they did not meet 
quality-control criteria, leaving 234,939 SNPs typed 
in 856 patients with Dupuytren’s disease and in 
2836 controls (Table 1). The call rate for the re-
maining SNPs was 99.9%. There was moderate evi-
dence for inflation in the test statistic (λgc = 1.21). 
Adjustment for differential population stratifica-
tion with the use of the first five components on the 
basis of a principal-component analysis of uncor-
related SNPs reduced the inflation to λgc = 1.19. 
Figure 2 in the Supplementary Appendix shows 
that the case and control groups were well matched 
for population stratification after correction for 
these components. We found that the inflation was 
caused by genetic heterogeneity between persons 
in the north and south in the Netherlands and not-
ed differences in case patients between the clin-
ics (Fig. 3 in the Supplementary Appendix). After 
exclusion of case patients from the most southern 
and eastern hospitals in the Netherlands, the in-
flation decreased to 1.07 (Fig. 4 and 5 in the Supple-
mentary Appendix). There were no signs of dif-
ferences in SNP call rates between case patients 
and controls. After correction for the inflation fac-
tor, the quantile–quantile plots of the logarithms 
of our genomewide P values showed 83 data 
points that were above the expected diagonal line 
(Fig. 1A).
In the genomewide association study, we iden-
tified eight SNPs at three loci that showed 
significant association (P<5×10−8) (Fig. 1B). On 
chromosome 7, we identified a locus with four 
significantly associated SNPs. Association was 
strongest at rs16879765, which lies within the gene 
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encoding ependymin-related protein 1 (EPDR1) 
(P = 1.9×10−16; odds ratio, 1.94). The three other 
associated SNPs were in linkage disequilibrium 
with the top SNP: rs1668357 (r2 = 0.57), rs1668347 
(r2 = 0.59), and rs952368 (r2 = 0.44). Similarly, three 
significantly associated SNPs were identified at 
a single locus on chromosome 22. The most sig-
nificant SNP on 22q, rs6519955 (P = 2.8×10−13; 
odds ratio, 1.56), is located between wingless-type 
mammary-tumor virus integration site family 
member 7B (WNT7B) and LOC100271722, a hypo-
thetical noncoding RNA gene. The two other as-
sociated SNPs on chromosome 22 were in link-
age disequilibrium with the top SNP: rs8140558 
(r2 = 0.96) and rs4072455 (r2 = 0.75). A conditional 
analysis to adjust for the top SNPs for these two 
loci showed no independent signals, suggesting 
that there is one pivotal genetic variation that 
drives the association of the neighboring SNPs. 
One additional putative Dupuy tren’s disease–asso-
ciated locus was identified on chromosome 19, with 
a single significant SNP (rs11672517) (P = 2.8×10−8; 
odds ratio, 1.46).
Tests of Replication
To test for replication of our initial findings, we 
selected 35 SNPs from 24 independent loci that 
met the significance threshold of P<1×10−4 in the 
discovery phase. We collected genotype data for 
the 35 SNPs in three different populations of case 
patients and controls, from the Netherlands, the 
United Kingdom, and Germany (1365 case patients 
with Dupuytren’s disease and 8445 controls before 
quality control). One SNP (rs10809642) failed on 
genotyping in the Dutch and U.K. replication series 
and four SNPs (rs1123148, rs2179367, rs638791, 
and rs12372139) failed genotyping because of a 
laboratory error in the German series. One SNP 
(rs1668357) was out of Hardy–Weinberg equilib-
rium (P<0.0001) in all three replication series and 
was therefore excluded from further analysis. Elev-
en SNPs from nine different regions showed 
clear evidence of replication after correction for 
the 35 tested SNPs (P<0.0014 and association with 
the same allele and in the same direction as in the 
discovery phase) and reached genomewide signifi-
cance in a meta-analysis (P<5.0×10−8) (Table 2, 
and the Supplementary Appendix). All loci that 
showed significant associations in the discovery 
set also showed significant associations in the 
replication set: rs16879765 (P = 5.6×10−39; odds ra-
tio, 1.98) on 7p14.1, rs6519955 (P = 3.2×10−33; odds 
ratio, 1.54) and rs8140558 (P = 1.2×10−22; odds ra-
tio, 1.39) on 22q13, and rs11672517 (P = 6.8×10−14; 
Table 1. Sample Collections and Genotyping Platforms for the Genomewide Association Study (GWAS) and Replications in Patients
with Dupuytren’s Disease and Control Subjects.*
Collection 
No. Country















 after QC Platform
GWAS





2 The Netherlands 189 184 KASP by Design 561 500 Illumina
HumanCytoSNP-12














Total 2325 2154 11,562 9972
* QC denotes quality control.
† In the original analysis, rs611744 was imputed in the U.K. control series. Subsequently, we directly genotyped this SNP in another set of 
8935 U.K. controls (WTCCC) with the use of the Immunochip array.
‡ In the German case series, several replication SNPs were genotyped in a separate control series that included 282 persons, and these were 
included in the main study. (For the SNP numbers, see Table 1 in the Supplementary Appendix.)
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odds ratio, 1.34) on 19q13.4. Two SNPs of border-
line significance in the discovery set showed sig-
nificant associations in the tests of replication: 
rs2912522 (P = 2.0×10−13; odds ratio, 0.72) on 8q13 
and rs8124695 ((P = 7.6×10−10; odds ratio, 1.48) on 
20q11.2–q13.1. Four additional SNPs also reached 
genomewide significance: rs611744 (P = 7.9×10−15; 
odds ratio, 0.75) on 8q23.1, rs10809650 (P = 6.2×10−9; 
odds ratio, 0.80) and rs10809642 (P = 1.2×10−8; odds 
ratio, 1.35) on 9p24.3, and rs7524102 (P = 2.8×10−9; 
odds ratio, 1.28) on 1p36.23–p35.1.
For 2 of the 11 SNPs with a significant genome-
wide association, we used tag SNPs with less than 
complete linkage disequilibrium or imputed SNPs 
in the meta-analysis (Table 1 in the Supplemen-
tary Appendix). We genotyped one of these SNPs, 
rs611744, on the Immunochip platform in 8274 
U.K. controls (Table 1) and observed an association 
(P = 1.8×10−14) on meta-analysis. The other SNP, 
rs8140558, is one of two SNPs at the WNT7B lo-
cus. In addition, a meta-analysis for this SNP that 
excluded the data from the U.K. and German series 
(since these data were only indirectly genotyped 
[Table 1 in the Supplementary Appendix]) showed a 
significant genomewide association (P = 4.8×10−16) 
(Table 3 in the Supplementary Appendix).
Regional plots of the nine Dupuytren’s disease 
risk loci are shown in Figure 6 in the Supplemen-
tary Appendix. To gain insight into the biologic 
mechanisms and to find genes functionally relat-
ed at these regions, we applied GRAIL analysis. The 
11 SNPs at the nine regions that had a sig nifi cant 
genomewide association were used as query re-
gions, resulting in the analysis of 22 unique genes. 
We found a total of seven associations with SNPs 
(P<0.05), including four SNPs implicating four 
WNT genes (P<0.0001 for each) (Table 4 in the 
Supplementary Appendix). When these results 
were corrected for multiple testing (22 tests), 
the associations with SNPs implicating the four 
WNT genes (rs7524102-WNT4, rs4730775-WNT2, 
rs6519955-WNT7B, and rs611744-RSPO2) remained 
significant (P<0.003). We observed no association 
between the identified SNPs with a significant 
genomewide association and gene expression in 
six quantitative-trait-locus data sets (see the Sup-
plementary Appendix).
Discussion
We identified nine chromosomal loci associated 
with susceptibility to Dupuytren’s disease. Very lit-
tle is known about the heritability of this disease, 
since there are only a few reports from family and 
twin studies.15­17 Our findings suggest that com-
mon genetic variants have an important causative 
role in Dupuytren’s disease in Northern Europe-
an populations.
A GRAIL analysis showed that four different 
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Figure 1. Results of the Genomewide Association Study in Dupuytren’s Disease.
The genomewide P values were obtained with the use of a basic chi-square allelic test with 1 degree of freedom, corrected for genomic 
inflation, for 234,939 SNPs in 856 patients with Dupuytren’s disease and 2836 controls from the Netherlands. Panel A is a quantile–
quantile plot of observed P values for association (blue) and after removal of SNPs within 1 megabase of the nine regions identified 
as significant after meta-analysis (green). The red line represents concurrence of the expected and the observed P values. Values above 
the red line indicate a signal in the data. Panel B is a Manhattan plot showing the genomewide P values (−log10) plotted against their 
 respective positions on each chromosome. The horizontal red line shows the genomewide significance threshold of 5.0×10−8.
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encode proteins in the Wnt-signaling pathway: 
1p36.23–p35.1, containing WNT4 (rs7524102); 
7q31.2, containing WNT2 (rs4730775); 22q13, 
containing WNT7B (rs6519955); and 8q23.1, con-
taining RSPO2 (rs611744). Three other associated 
loci also contain WNT genes, although they were 
not implicated on GRAIL analysis: 7p14.1, con-
taining SFRP4 (rs16879765); 8q13, containing 
SULF1 (rs2912522); and 6q25.1, containing TAB2 
(rs2179367). However, the last of these three did not 
reach genomewide significance (Pmeta = 2.5×10−7).
The WNT gene family consists of structurally 
related genes that encode glycoproteins, extracel-
lular signaling molecules. Abnormal Wnt signal-
ing is linked to a range of diseases, especially 
cancer. The best-understood Wnt-signaling path-
way is the canonical pathway, which activates the 
nuclear functions of β-catenin, leading to chang-
es in gene expression that influence cell prolif-
eration and survival.18 Abnormal proliferation of 
fibroblasts is a key feature in the early develop-
ment of Dupuytren’s disease. The disease can be 
divided into three histologic stages: stage 1, pro-
liferation of fibroblasts; stage 2, differentiation 
of fibroblasts into myofibroblasts; and stage 3, 
formation of mature type 1 collagen.19,20 Wnt sig-
naling is known to regulate the proliferation and 
differentiation of fibroblasts in both cancer and 
fibromatosis.21 Most of our knowledge of Wnt 
signaling is derived from studies of cancer. In co-
lon cancer, up-regulation of Wnt signaling causes 
intestinal crypt cells to proliferate for longer than 
usual before they migrate and differentiate.22 This 
prolonged proliferation phase results in the for-
mation of polyps and confers a predisposition to 
cancer.
The involvement of the Wnt-signaling pathway 
in the pathogenesis of Dupuytren’s disease is con-
sistent with features of the disease and with estab-
lished aspects of Wnt signaling. An imbalance of 
Wnt signaling in Dupuytren’s disease could cause 
fibroblasts in the fascia of the hand to prolifer-
ate and form nodules. Indeed, increased levels of 
β-catenin have been observed in primary cell 
cultures in vitro,23 suggesting that the Wnt-sig-
naling pathway is overstimulated in Dupuytren’s 
disease.
The Wnt proteins Wnt2, Wnt4, and Wnt7B, 
which were identified on GRAIL analysis, bind 
to frizzled receptors, leading to a cascade of 
events that eventually result in a decrease in the 
rate of β-catenin degradation18 (Fig. 2). Secreted 
frizzled-related proteins, such as SFRP4, antago-
nize the Wnt-signaling pathway by binding to 
either Wnts or frizzled receptors, thereby affect-
ing receptor occupancy. In the absence of active 
Wnt, β-catenin is degraded, and potential target 
genes will not be activated.
Another Dupuytren’s disease risk locus contains 
RSPO2, encoding an R-spondin; members of the 
R-spondin family interact with frizzled receptors 
and LRP5/6 to induce β-catenin signaling. Fur-
thermore, R-spondins induce canonical Wnt sig-
naling by competing with the dickkopf (DKK) 
protein for binding to LRP5/6. The DKK protein 
is an inhibitor of Wnt signaling; it hinders the 
formation of a complex among Wnt, frizzled re-
ceptor, and LRP5/6 (Fig. 2).25 SULF1, a heparan 
sulfate 6-O-endosulfatase, is known to influence 
canonical Wnt signaling. How it does so is not 
clear, but 6-O-desulfation of heparan sulfate pro-
teoglycans may alter the binding of Wnt to its 
frizzled receptor.26,27 Increased activity of these 
WNT and R-spondin genes or decreased activity 
of SFRP could stimulate Wnt signaling and re-
duce intracellular β-catenin degradation. This 
mechanism could trigger fibroblasts to prolifer-
ate, leading to the development of Dupuytren’s 
disease.
Also supporting a role for Wnt signaling in 
Dupuytren’s disease is the microRNA (miRNA) 
expression profiles of fibroblasts and palmar fas-
cia in persons with this disease, as compared with 
those in healthy controls. These miRNAs regulate 
genes related to the β-catenin pathway: WNT5A, 
ZIC1, and TGFB1.28 The three remaining significant 
loci lack an obvious connection to the Wnt path-
way. An interesting candidate gene from these re-
gions is MAFB. The RNA of MAFB has been shown 
to be up-regulated in the excised cord tissue from 
persons with Dupuytren’s disease, as compared 
with fascia of the hand in healthy controls.29 
Maf proteins are known for their role in fibro-
sarcoma and are believed to influence tissue 
development and cellular differentiation.30 MAFB 
can transform primary fibroblasts in vitro.31 The 
gene might therefore be involved in stage 2 of Du-
puytren’s disease (the differentiation of fibroblasts 
into myofibroblasts). The miRNA expression pro-
file associated with Dupuytren’s disease impli-
cated some miRNAs in influencing the expres-
sion of MAFB as well.28
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The results of our study indicate that genetic 
factors have a major role in the development of 
Dupuytren’s disease. Associations with variations 
in genes that encode proteins in the Wnt-signaling 
pathway suggest that aberrations in this path-
way confer susceptibility to the disease. Further 
genetic and basic research is required to fully un-
ravel the pathogenesis of Dupuytren’s disease.
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